Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Transplant ; 26(1): 123-32, 2012.
Article in English | MEDLINE | ID: mdl-21401720

ABSTRACT

BACKGROUND: Rabbit anti-thymocyte globulin (rATG) induction reduces reperfusion injury and improves renal function in kidney recipients by means of properties unrelated to T-cell lysis. Here, we analyze intensive rATG induction (single dose, rATG(S) , vs. divided dose, rATG(D) ) for improved renal function and protection against hyperglycemia. METHODS: Patients without diabetes (n = 98 of 180) in a prospective randomized trial of intensive rATG induction were followed for six months for the major secondary composite end point of impaired glucose regulation (hyperglycemia and new-onset diabetes after transplantation, NODAT). Prospectively collected data included fasting blood glucose and HbA(1c). Serum Mg(++) was routinely collected and retrospectively analyzed. RESULTS: Induction with rATG(S) produced less impaired glucose regulation (p = 0.05), delayed NODAT development (p = 0.02), less hyperglycemia (p = 0.02), better renal function (p = 0.04), and less hypomagnesemia (p = 0.02), a factor associated with a lower incidence of NODAT. Generalized linear modeling confirmed that rATG(S) protects against a synergistic interaction between tacrolimus and sirolimus that otherwise increased hypomagnesemia (p = 0.008) and hyperglycemia (p = 0.03). CONCLUSIONS: rATG(S) initiated before renal reperfusion improved early renal function and reduced impaired glucose regulation, an injury by diabetogenic maintenance agents (tacrolimus and sirolimus).


Subject(s)
Antilymphocyte Serum/administration & dosage , Blood Glucose/metabolism , Diabetes Mellitus/prevention & control , Graft Rejection/prevention & control , Hyperglycemia/prevention & control , Kidney Transplantation , Renal Tubular Transport, Inborn Errors/prevention & control , Adult , Aged , Animals , Diabetes Mellitus/etiology , Female , Follow-Up Studies , Humans , Hyperglycemia/etiology , Immunosuppressive Agents/therapeutic use , Kidney Function Tests , Male , Middle Aged , Prognosis , Prospective Studies , Rabbits , Renal Tubular Transport, Inborn Errors/etiology , Survival Rate , Young Adult
2.
Transplantation ; 85(10): 1391-9, 2008 May 27.
Article in English | MEDLINE | ID: mdl-18497677

ABSTRACT

BACKGROUND: The optimal dosing protocol for rabbit anti-thymocyte globulin (rATG) induction in renal transplantation has not been determined, but evidence exists that rATG infusion before renal allograft reperfusion improves early graft function. Infusing a large rATG dose over a short interval has not previously been evaluated for its effect on renal function and allograft nephropathy in a prospective, randomized comparison against conventional rATG induction. METHODS: Between April 20, 2004 and December 26, 2007 we enrolled renal transplant patients into a prospective, randomized, nonblinded trial of two rATG dosing protocols (single dose, 6 mg/kg vs. divided doses, 1.5 mg/kg every other day x 4; target enrollment=160) followed after 6 months by calcineurin-inhibitor withdrawal. Primary endpoints are renal function by calculated glomerular filtration rate (GFR) and chronic allograft nephropathy at protocol biopsy. We now present the early GFR data of all 160 patients and safety and efficacy data of the first 142 patients with 6 months follow up and before calcineurin inhibitor withdrawal (average follow up=23.3+/-11.6 months). RESULTS: There were no differences between groups in rATG-related adverse events, patient and graft survival, acute rejection, or chronic allograft nephropathy rate at 6 months. Calculated DeltaGFR (POD 1-4) was significantly better in the single-dose group (P=0.02), with a trend toward improved renal function from months 2 to 6 in recipients of deceased donor kidneys (P=0.08). CONCLUSIONS: This study demonstrates that administering 6 mg/kg of rATG over 24 hr is safe and is associated with improved early renal function compared with administering rATG in alternate-day doses.


Subject(s)
Antilymphocyte Serum/therapeutic use , Kidney Transplantation/immunology , Adult , Animals , Antilymphocyte Serum/administration & dosage , Drug Administration Schedule , Drug Monitoring/methods , Drug Therapy, Combination , Female , Glomerular Filtration Rate , Graft Survival/drug effects , Humans , Kidney Transplantation/adverse effects , Kidney Transplantation/mortality , Male , Middle Aged , Patient Selection , Rabbits , Sirolimus/therapeutic use , Survival Analysis , Tacrolimus/therapeutic use , Transplantation, Homologous
SELECTION OF CITATIONS
SEARCH DETAIL
...